Safety and Efficacy of CD19 Chimeric Antigen Receptor T-Cell (CAR-T) in the Treatment of Refractory Membranous Nephropathy

NCT07266181 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Refractory Membranous Nephropathy

Interventions

OTHER: All patients will receive CD19 CAR-T cell therapy on the basis of standard symptomatic and supportive treatment.

Sponsor

The First Affiliated Hospital of Air Force Medicial University